Meeting
2014 ASCO Annual Meeting
Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.
Authors
Yvonne H. Yeung
Ludwig Institute for Cancer Research, Heidelberg, Australia
Yvonne H. Yeung , Fiona J.M. Chionh , Timothy Jay Price , Andrew Mark Scott , Hoanh Tran , Guangying Fang , Effie Skrinos , Carmel Murone , John M Mariadason , Niall C. Tebbutt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT00973713
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4101)
DOI
10.1200/jco.2014.32.15_suppl.4101
Abstract #
4101
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Hong Zong